<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658020</url>
  </required_header>
  <id_info>
    <org_study_id>DW224-III-3</org_study_id>
    <nct_id>NCT01658020</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg</brief_title>
  <acronym>DW224-III-3</acronym>
  <official_title>Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chosun University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KangWon National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of Korea Saint Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masan Samsung Hospital, South Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple
      dose of Zabofloxacin Tablet 400 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, Multicenter, Double Blind, Active Controlled, Randomized Study to Evaluate the
      Efficacy and Safety of Zabofloxacin for Patients with acute bacterial exacerbation of Chronic
      obstructive pulmonary disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response in the Clinical Populations</measure>
    <time_frame>10days</time_frame>
    <description>Clinical response corresponding clinical cure at Test of Cure visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response in the Clinical Population</measure>
    <time_frame>36days</time_frame>
    <description>Clinical response corresponding clinical cure at End of Study visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure Rate in the Microbiological Per Protocol(PP) Population</measure>
    <time_frame>10days</time_frame>
    <description>Clinical response corresponding clinical cure in the microbiological per-protocol population.
Microbiological responses were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Response Rate</measure>
    <time_frame>10days</time_frame>
    <description>Microbiological response rate in the microbiological per protocol(PP) population.
Microbiological rate were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EXACT-PRO Score</measure>
    <time_frame>10 days</time_frame>
    <description>The outcome measurement is Change in EXACT-PRO score for clinical populations at Test of cure visit.
EXACT-PRO means that the questionnaires for Exacerbation of Chronic Pulmonary Disease Tool-Patient Reported Outcome of United BioSource Corporation(UBC) of USA that had been standardized, equipped with reliability and feasibility applicable to various COPD patients groups were used in order to quantitate frequency, severity and duration of acute exacerbation as a tool to measure acute exacerbation of COPD.
EXACT-PRO is consisted of 14 questionnaire items were classified into 3 domains, Respiratory Distress Domain, Cough/Sputum Domain, and Chest Symptoms Domain. The Scores of each domain were to be summed into the domain raw summed score or converted into EXACT domain score according to the conversion table. The total score had value in the range from 0 to 100 and higher the value was, severer the respiratory symptoms were in evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CAT Scores</measure>
    <time_frame>10 days</time_frame>
    <description>The outcome measurement is Change in CAT scores for clinical populations at Test of cure visit.
CAT score means that COPD Assessment Test was used as a tool to assess the effects of COPD on physical, mental status and daily life.
CAT is consisted of 8 items in total and each question item was scored from 0 point to 5 point.
The scores of each question item were summed into the total score, which had values between 0 and 40.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>DW224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avelox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400mg tablet P.O. once daily for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin</intervention_name>
    <description>Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days</description>
    <arm_group_label>DW224</arm_group_label>
    <other_name>DW224</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 400mg tablet P.O. once daily for 7days</description>
    <arm_group_label>Avelox</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female same or older than age of 40

          -  Severity of acute exacerbation of Chronic obstructive pulmonary disease(COPD) must
             suit oral administration treatment

          -  Diagnosed as COPD before receiving written informed consent and outcome measure of
             spirometry testing confirmed as [Ratio of Forced Expiratory Volume in 1 second(FEV1)
             to Forced Vital Capacity(FVC)](FEV1/FVC) &lt; 0.7

          -  Subject showing following signs and symptoms:

             (i)Purulent Sputum or Sputum level is increased (ii)Difficulty in breathing is
             increased

          -  Female subjects who might be pregnant must do pregnancy test and results should be
             negative before randomization is done. She must receive written informed consent form
             (NOTE: Subject who has used single hormone contraception for pregnancy control or has
             not been more than 1 year after Tubule ligation and menopause are excluded from the
             study)

          -  Subject who can agree and sign written informed consent form approved by Institutional
             Review Board(IRB) before participating in study and follow study requirements

        Exclusion Criteria:

          -  Subject who administered excess daily dose of antimicrobial/antibiotics in past 72
             hours before receiving written consent

          -  Diagnosed to have pneumonia by taking chest X-ray in past 48 hours before receiving
             written consent

          -  Diagnosed to have infectious diseases or such diseases results in complications before
             receiving written consent (NOTE: Septic shock, Bronchiectasis, Lung abscess,
             Pneumonia, Active tuberculosis, Pulmonary malignancy, Cystic fibrosis, Empyema,
             Asthma)

          -  Have kidney or liver diseases who correspond following criteria:

             (i) Creatinine Clearance(CCr) &lt; 50 mL/min (ii) Blood Urea Nitrogen(BUN) â‰¥ 30 mg/dl
             (iii) Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 3 x Upper
             Limit Normal(ULN) (iv) Total bilirubin &gt; 2 x ULN (v) Alkaline Phosphatase(ALP) &gt; 2 x
             ULN.

          -  Organic gastrointestinal disorder having abnormal absorption problem condition in past
             6 months before receiving written consent (NOTE: Active Crohn's disease, active
             ulcerative colitis)

          -  Diagnosed to have neutropenia where absolute neutrophil count is &lt; 1,000cells/mm3
             (NOTE: Even though subject neutrophil count is &lt; 1,000cells/mm3, if it is acute
             infection, subject maybe possible to participate)

          -  Chronic Hepatitis B carrier

          -  Have proof that subject is Hepatitis C carrier or have Hepatitis C antibody

          -  Immunodeficiency diseases such as HIV positive, AIDS, Bone marrow transplant or
             leukemia

          -  Have medical history of hypersensitive reaction to antibiotics of fluoroquinolones

          -  Have medical history of seizure or administration of anti-seizure drug in past 1 year
             before receiving written consent (NOTE: Epilepsy, Convulsions, Myasthenia gravis)

          -  Medical history of ventricular arrhythmia

          -  Medical history of QTc prolongation or currently administering drug that delays QTc
             interval (NOTE: QTc prolongation means QTc interval &gt; 450 msec)

          -  Complex infections or diseases that can effect study assessment or need long-term
             antibiotic treatment exceeding 7 days

          -  Subject who has participated in Clinical trials or Bioequivalence test in past 30 days
             before receiving written consent

          -  Clinically significant by observations considered as unsuitable based on medical
             judgement by investigators where current condition can effect quality of safety or
             data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeon-Mok Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Do Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://medical.amc.seoul.kr/medservice/main/main.do</url>
    <description>Asan Medical Center</description>
  </link>
  <link>
    <url>http://www.dong-wha.co.kr/dw_main.asp</url>
    <description>Dong Wha Pharm. Co. Ltd.</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <results_first_submitted>September 1, 2014</results_first_submitted>
  <results_first_submitted_qc>September 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2014</results_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute exacerbation of Chronic obstructive pulmonary disease</keyword>
  <keyword>Acute Exacerbation</keyword>
  <keyword>Chronic obstructive pulmonary disease(COPD)</keyword>
  <keyword>Zabofloxacin</keyword>
  <keyword>Moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DW224</title>
          <description>Zabofloxacin 400mg tablet P.O. once daily for 5days and Placebo P.O. once daily</description>
        </group>
        <group group_id="P2">
          <title>Avelox</title>
          <description>Moxifloxacin 400mg tablet P.O. once daily for 7days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DW224</title>
          <description>Zabofloxacin 367mg tablet P.O. once daily for 3 days and then placebo P.O. once daily for 2 days</description>
        </group>
        <group group_id="B2">
          <title>Avelox</title>
          <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="342"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.76" spread="7.79"/>
                    <measurement group_id="B2" value="68.40" spread="8.04"/>
                    <measurement group_id="B3" value="68.07" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response in the Clinical Populations</title>
        <description>Clinical response corresponding clinical cure at Test of Cure visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
        <time_frame>10days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response in the Clinical Populations</title>
          <description>Clinical response corresponding clinical cure at Test of Cure visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.71" lower_limit="81.15" upper_limit="92.28"/>
                    <measurement group_id="O2" value="86.26" lower_limit="80.36" upper_limit="92.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response in the Clinical Population</title>
        <description>Clinical response corresponding clinical cure at End of Study visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
        <time_frame>36days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response in the Clinical Population</title>
          <description>Clinical response corresponding clinical cure at End of Study visit. Based on the clinical outcomes, the results of assessment were classified into Clinical Cure, Clinical Failure, Relapse and Indeterminate.</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.22" lower_limit="69.25" upper_limit="83.20"/>
                    <measurement group_id="O2" value="70.99" lower_limit="63.22" upper_limit="78.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure Rate in the Microbiological Per Protocol(PP) Population</title>
        <description>Clinical response corresponding clinical cure in the microbiological per-protocol population.
Microbiological responses were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
        <time_frame>10days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure Rate in the Microbiological Per Protocol(PP) Population</title>
          <description>Clinical response corresponding clinical cure in the microbiological per-protocol population.
Microbiological responses were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.37" lower_limit="78.79" upper_limit="97.95"/>
                    <measurement group_id="O2" value="94.87" lower_limit="87.95" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Response Rate</title>
        <description>Microbiological response rate in the microbiological per protocol(PP) population.
Microbiological rate were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
        <time_frame>10days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Response Rate</title>
          <description>Microbiological response rate in the microbiological per protocol(PP) population.
Microbiological rate were discriminated for the pathogens isolated from the respiratory secretion samples of subjects.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.44" lower_limit="53.44" upper_limit="81.45"/>
                    <measurement group_id="O2" value="79.49" lower_limit="66.81" upper_limit="92.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EXACT-PRO Score</title>
        <description>The outcome measurement is Change in EXACT-PRO score for clinical populations at Test of cure visit.
EXACT-PRO means that the questionnaires for Exacerbation of Chronic Pulmonary Disease Tool-Patient Reported Outcome of United BioSource Corporation(UBC) of USA that had been standardized, equipped with reliability and feasibility applicable to various COPD patients groups were used in order to quantitate frequency, severity and duration of acute exacerbation as a tool to measure acute exacerbation of COPD.
EXACT-PRO is consisted of 14 questionnaire items were classified into 3 domains, Respiratory Distress Domain, Cough/Sputum Domain, and Chest Symptoms Domain. The Scores of each domain were to be summed into the domain raw summed score or converted into EXACT domain score according to the conversion table. The total score had value in the range from 0 to 100 and higher the value was, severer the respiratory symptoms were in evaluation.</description>
        <time_frame>10 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EXACT-PRO Score</title>
          <description>The outcome measurement is Change in EXACT-PRO score for clinical populations at Test of cure visit.
EXACT-PRO means that the questionnaires for Exacerbation of Chronic Pulmonary Disease Tool-Patient Reported Outcome of United BioSource Corporation(UBC) of USA that had been standardized, equipped with reliability and feasibility applicable to various COPD patients groups were used in order to quantitate frequency, severity and duration of acute exacerbation as a tool to measure acute exacerbation of COPD.
EXACT-PRO is consisted of 14 questionnaire items were classified into 3 domains, Respiratory Distress Domain, Cough/Sputum Domain, and Chest Symptoms Domain. The Scores of each domain were to be summed into the domain raw summed score or converted into EXACT domain score according to the conversion table. The total score had value in the range from 0 to 100 and higher the value was, severer the respiratory symptoms were in evaluation.</description>
          <population>Per protocol population</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.90" spread="9.59"/>
                    <measurement group_id="O2" value="-4.29" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CAT Scores</title>
        <description>The outcome measurement is Change in CAT scores for clinical populations at Test of cure visit.
CAT score means that COPD Assessment Test was used as a tool to assess the effects of COPD on physical, mental status and daily life.
CAT is consisted of 8 items in total and each question item was scored from 0 point to 5 point.
The scores of each question item were summed into the total score, which had values between 0 and 40.</description>
        <time_frame>10 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>DW224</title>
            <description>Zabofloxacin 367mg tablet P.O. once daily for 5 days and then placebo P.O. once daily for 2 days</description>
          </group>
          <group group_id="O2">
            <title>Avelox</title>
            <description>Moxifloxacin 400mg tablet P.O. once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CAT Scores</title>
          <description>The outcome measurement is Change in CAT scores for clinical populations at Test of cure visit.
CAT score means that COPD Assessment Test was used as a tool to assess the effects of COPD on physical, mental status and daily life.
CAT is consisted of 8 items in total and each question item was scored from 0 point to 5 point.
The scores of each question item were summed into the total score, which had values between 0 and 40.</description>
          <population>Per protocol population</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="5.88"/>
                    <measurement group_id="O2" value="-2.48" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>About 1.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DW224</title>
          <description>Zabofloxacin Tablet 400mg given by oral administration
Moxifloxacin Tablet 400mg: multiple-dose</description>
        </group>
        <group group_id="E2">
          <title>Avelox</title>
          <description>Moxifloxacin Tablet 400mg given by oral administration
Zabofloxacin Tablet 400mg: multiple-dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vimiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Red blood cell microcytes present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sputum retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Asan Midical Center</organization>
      <phone>+82-2-3010-3136</phone>
      <email>ymoh55@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

